Deutsche Bank Downgrades Sanofi (SNY) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
Jefferies Downgrades Sanofi (SNY) to Hold
October 29, 2014 8:54 AM EDTJefferies downgraded Sanofi (NYSE: SNY) from Buy to Hold.
For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.
Shares of Sanofi closed at $48.07 yesterday.
... MoreBofA/Merrill Lynch Downgrades Sanofi-Aventis (SNY) to Neutral on CEO Removal
October 29, 2014 8:47 AM EDTBofA/Merrill Lynch downgraded Sanofi-Aventis (NYSE: SNY) from Buy to Neutral with a price target of $48.00 after the announcement that it has unanimously voted to remove Chris Viehbacher from his position as CEO.
Analyst Graham Parry said the news is negative for several... More
Barclays Downgrades Sanofi (SNY) to Equalweight
October 29, 2014 8:35 AM EDTBarclays downgraded Sanofi (NYSE: SNY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.
Shares of Sanofi closed at $48.07 yesterday.
... MoreSanofi (SNY) Reports Q3 EPS of EUR1.47
October 28, 2014 6:42 AM EDTSanofi (NYSE: SNY) reported Q3 EPS of EUR1.47, EUR0.01 better than the analyst estimate of EUR1.46. Revenue for the quarter came in at EUR8.78 billion.
On diabetes, the company said, "Third-quarter sales of the Diabetes division reached 1,799 million, an increase of 8.3%. Year-to-date sales of the Diabetes division increased 12.5% to 5,249 million. Lantus® sales increased 8.1% to 1,567 million in the third... More
